Abstract 135P
Background
Two classical models have been proposed for the development of colorectal cancer (CRC) from colon epithelial cells, transformation of adenoma and serrated polyps to cancer. However, clinical data showed that there is still a certain amount of CRC is not derived from the above two pathways, forming the theoretical island of CRC pathogenesis. Laterally spreading tumor (LST) is an important precancerous lesion of CRC, while the molecular mechanism of it's carcinogenesis remained unclear.
Methods
We proposed a two-stage cascade mutation hypothesis for LST cancerization. Based on the mRNA data of 25711 samples from 980 healthy donors in the genotype-tissue expression, pan-cancer mRNA-sequencing and survival data.We performed a differential expression and survival analysis of ATM, ANO5, APC, and TP53 in pan-cancer and adjacent normal samples. Furthermore, we validated the noneffective role of PIK3CA signaling pathway in two cell lines, LS174T and SW1116 by constructing three SiRNA (PIK3CA-SiRNA-1, PIK3CA-SiRNA-2, PIK3CA-SiRNA-3), to confirm the vital role of TGFβ and p53 signaling pathway involving in LST cancerization.
Results
The expression profiles of ATM, ANO5, APC and TP53 in normal and pan-cancer samples were significantly downregulated in rectal adenocarcinoma, colon adenocarcinoma, and their joint samples. In contrast, TP53 showed an obviously higher level in all of above samples. ATM, ANO5, APC, and TP53 expression were correlated with the overall survival of colorectal cancer patients. ATM and ANO5, which closely related to the Golgi apparatus fragmentation in LST samples presented a significant changes. The SiRNA interference test showed that the expression level of PIK3CA was not significantly different from the control group.
Conclusions
These findings suggested that early APC mutations induced a Golgi fragmentation event, weakened the expression of wild-type TP53 transcription factor MDM2 and TP73, modulated the stability of mutant TP53, ultimately promoted the carcinogenesis process of the LST. The PI3K signaling pathway is not closely associated with LST carcinogenesis. These observations suggest the existence of a unique and novel pathway for the development of CRC from LST.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China; Gansu Medical College.
Disclosure
The authors have declared no conflicts of interest.
Resources from the same session
71P - When neighbors play a role: The importance of interacting proteins in the tumorigenic effect of cancer driver genes
Presenter: Margarida Carrolo
Session: Cocktail & Poster Display session
Resources:
Abstract
72P - SNCG promotes the malignant progression of hepatocellular carcinoma by activation EGFR signaling and recycling
Presenter: Yue Chen
Session: Cocktail & Poster Display session
Resources:
Abstract
73P - TROP2 amplification is highly present in dedifferentiated liposarcoma: Data from the Cancer Genome Atlas (TCGA) in soft tissue sarcoma
Presenter: Sarah Orlando
Session: Cocktail & Poster Display session
Resources:
Abstract
74P - The influence of genetic phenotype on prognosis of osteosarcoma
Presenter: Nasirov Kamalovich
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Immune engager compounds screening using CRC patient-derived organoids
Presenter: Claudia Maria A. Pinna
Session: Cocktail & Poster Display session
Resources:
Abstract
77P - Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer
Presenter: Juan Jiménez-Vacas
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - Exploring ecDNA heterogeneity and evolution in non-small cell lung cancer
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
79P - Targeting galectin-9 in BRCA mutant breast cancer
Presenter: Chun Yan So
Session: Cocktail & Poster Display session
Resources:
Abstract
80P - Suppression of glioblastoma progression by FDA-approved central nervous system-accumulating drugs via autophagy modulation and ER stress-induced apoptosis
Presenter: Smita Dey
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Evaluating the effect of lenvatinib-resistance in hepatocellular carcinoma cells and in lenvatinib-resistant patient-derived PBMCs
Presenter: Luisa Amato
Session: Cocktail & Poster Display session
Resources:
Abstract